Clinical study on recombinant humanized anti-CD25 monoclonal antibody used for treating steroid-resistant acute graft versus host disease following allo-hematopoietic stem cell transplantation.
10.7534/j.issn.1009-2137.2013.06.032
- Author:
Xiao-Hong LI
1
;
Chun-Ji GAO
1
;
Wan-Ming DA
1
;
Yong-Bin CAO
1
;
Li-Xin XU
1
;
Ya-Mei WU
1
;
Bei LIU
1
;
Zhou-Yang LIU
1
;
Bei YAN
1
;
Song-Wei LI
1
;
Xue-Liang YANG
1
;
Xiao-Xiong WU
2
Author Information
1. Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China.
2. Department of hematology, The First Affiliated Hospital, Chinese PLA General Hospitall, Beijing 100037, China. E-mail: xiongwuxiao@sohu.com.
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Antibodies, Monoclonal, Humanized;
immunology;
therapeutic use;
Child;
Child, Preschool;
Drug Resistance, Neoplasm;
Female;
Graft vs Host Disease;
drug therapy;
Hematopoietic Stem Cell Transplantation;
methods;
Hormones;
pharmacology;
Humans;
Interleukin-2 Receptor alpha Subunit;
immunology;
Male;
Middle Aged;
Transplantation, Homologous;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(6):1535-1540
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the efficacy and feasibility of recombinant humanized anti-CD25 monoclonal antibody for treating steroid-resistant acute graft-versus-host disease (aGVHD ) following allo-hematopoietic stem cell transplantation (allo-HSCT) . Twenty-one cases with II-IV grade steroid-resistant aGVHD after allo-HSCT were treated by intravenous injection of recombinant humanized anti-CD25 monoclonal antibody at a dose of 1 mg/(kg·d) on days 1, 4, 8. Injection was repeated after 1 week for the patients who did not achieve CR. The results indicated that 13 cases (61.9%) got complete response (CR), 4 cases out of them have been still in disease-free survival, 8 cases have been in survival with mild cGVHD, 1 cases died from AML relapse, 6 cases (28.57%) got partial response (PR), 3 cases out of them have been in survival with mild cGVHD, 3 case died from pulmonary infection, 2 cases without response died from GVHD. Overall response rate was 90.5% and long term survival rate was 71.48%. There were no infusion-associated side-effects after treatment with recombinant humanized anti-CD25 monoclonal antibody.It is concluded that recombinant humanized anti-CD25 monoclonal antibody is effective and feasible for treatment of steroid-refractory grade II-IV aGVHD after allo-HSCT.
